IRDye® 800CW PEG Contrast Agent

Enhanced permeability and retention (EPR) is a common characteristic of tumor vasculature. The vascular endothelium in the tumor microenvironment is often discontinuous, allowing molecules to diffuse into the surrounding tumor tissue. [1,2] In addition to EPR, the lymphatic drainage for these regions is poor [3]. Hence, larger molecules tend to accumulate.

IRDye 800CW PEG Contrast Agent (25-60 kDa) is a non-specific imaging agent intended to exploit EPR in tumor biology. In appropriate mouse models, the agent highlights surface vasculature for approximately 0.5 hour post injection as seen in Figure 1. Approximately 4 hours post injection, retention of the labeled macromolecule is visible in the tumor (Figure 2). At 9 hours post intravenous injection the tumor is well defined (Figure 3).

In addition, IRDye 800CW PEG Contrast Agent may also be used effectively as a lymph tracking agent when given intradermally (Figure 4). Images captured on the Pearl^® Imaging System.

[LEFT] Figure 1. Athymic male nu/nu mouse (~5-6 wks old) 0.5 hour after receiving IRDye 800CW PEG (1 nmole) intravenously. Surface blood vessels are visible.  Vascular feature is mouse model dependent, see pack insert for Precautions.

[LEFT] Figure 2.  Athymic male nu/nu mouse approximately 4 hours after receiving IRDye 800CW PEG  (1 nmole) intravenously.  Large blood vessels and tumor are visible.

[LEFT] Figure 3.  Athymic male nu/nu mouse approximately 9 hours after receiving IRDye 800CW PEG (1 nmole) intravenously. Tumor is clearly defined.

[LEFT] Figure 4.  Athymic male nu/nu mouse minutes after receiving IRDye 800CW PEG (~0.1 nmole) intradermally on the tail (right side). Image highlights use of IRDye PEG as a lymph imaging agent.

Ordering Information:

Please see our new Online Catalog for the latest ordering information.

Advantages of BrightSite™ Optical Agents

• High signal-to-noise ratio

• Low NIR autofluorescence from tissues, cells, biological materials, and drug compounds

• IRDye 800CW absorption/emission near 800 nm matches NIR absorption minima for bodily fluids and tissues, resulting in excellent tissue penetration

Molar extinction coefficient characteristics of water, hemoglobin and oxygenated hemoglobin (400-1000 nm). IRDye^® infrared dyes have ideal excitation/emission wavelengths for in vivo imaging

IRDye 800CW PEG Contrast Agent is a non-specific imaging agent intended to exploit EPR in tumor biology. In appropriate mouse models, the agent highlights surface vasculature for approximately 0.5 hour post injection. Approximately 4 hours post injection, retention of the labeled macromolecule is visible in the tumor. At 9 hours post intravenous injection the tumor is well defined.

In addition, IRDye 800CW PEG Contrast Agent may also be used effectively as a lymph tracking agent when given intradermally.

Brochures & Data Sheets

• BrightSite™ Small Animal Imaging Agents Brochure

• BrightSite™ Small Animal Imaging Agents Data Sheet

• Pearl^® Impulse Small Animal Imaging Brochure

• IRDye 800CW PEG Contrast Agent Data Sheet

Webinars

• Cancer Research Webinar Series Part 5: Target Fluorescent Contrast Agents for Image-Guided Cancer Surgery
  - Dr. D. Michael Olive

• Cancer Research Webinar Series Part 3: In Vivo Imaging with Near-Infrared Fluorescent Optical Probes
  - Dr. Amy Geschwender

• Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer
  - Dr. Eva Sevick-Muraca and Dr. Shi Ke, Baylor College of Medicine

• Systematic Evaluation of Targeted IRDye^® Labeled Optical Imaging Agents
  - Joy Kovar, Sr. Scientist

• More Small Animal in vivo Imaging Webinars